Papp KA, et al. - Researchers compared the outcomes with guselkumab, placebo and adalimumab utilizing the novel, validated Psoriasis Symptoms and Signs Diary (PSSD) in patients with moderate-to-severe psoriasis. They randomized the patients to guselkumab 100 mg every 8 weeks; placebo-to-guselkumab 100 mg every 8 weeks; or adalimumab 40 mg every 2 weeks. Patients treated with guselkumab demonstrated greater improvements in symptoms and signs of psoriasis vs those treated with placebo at week 16 or adalimumab through 48 weeks.